Thursday, June 30, 2022


Aptamer Group Signs Deal with Flip Gene Therapeutics to Support the Development of Inducible Gene Therapies

Latest Posts

Kyowa Kirin Expands License Agreement with Synaffix and Takes Exclusive Target Rights Based on Latest Positive ADC Data

The technology licensed from Synaffix include GlycoConnect™, HydraSpace™, and multiple toxSYN™ linker-payloads, which allow for the drug-to-antibody ratio (DAR) to be tailored to 1, 2 or 4 to optimize the therapeutic index of the ADC.

Ingenza Awarded Government Funding

Ingenza advises the project aims to develop a novel CO2 conversion technology, which will capture industrial CO2 emissions and convert them into formate, a versatile chemical that can be used across various industries, including pharmaceuticals and agriculture.

MultiOmic Health and Mesh Bio Partner to Use AI to Develop Precision Medicines & Diagnostics for Chronic Metabolic Disease

MultiOmic Health advises the partnership will provide access to data from patient populations in Asia that have historically been underrepresented in chronic metabolic disease studies.

BD Launches Combination Test for COVID-19, Influenza A/B and Respiratory Syncytial Virus

BD notes the test uses a single nasal swab or a single nasopharyngeal swab sample to determine if a patient has COVID-19 or the flu or RSV. It helps eliminate the need for multiple tests or doctor visits and can help clinicians to implement the right treatment plan quickly.

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has negotiated a deal with the biotechnology company Flip Gene Therapeutics to support its novel, inducible gene therapy platform with the use of Optimer technology.

The agreement will see Aptamer Group develop Optimer binders to several small molecule targets. The developed Optimers will be incorporated into the partner’s gene therapy platform with the goal of developing pharmacologically inducible gene therapeutics controllable with a gene switch.

Gene therapies are an innovative class of therapeutics which treat diseases and conditions through the delivery of genetic material. A wave of recent progress has reinforced the potential of the approach; however, major gene therapy platforms do not allow for precise control of gene expression after the therapy is administered. The use of the Optimer binders as a component of a gene switch in a gene therapeutic could enable responsive gene expression that could be controlled by dosing certain small molecule drugs.

The commercial terms of the agreement include initial upfront payments for Optimer development, with the potential for further licensing payments for the developed Optimer binders, and development and commercial milestone payments upon clinical and commercial success.

Optimer binders are oligonucleotide-based affinity ligands. The Optimer platform consists of three parallel target-type specific discovery processes for small molecules, proteins and peptides and cell targets. Delivering the potential for increased success in discovery over a broader target range and the ability to tune their half-life, they offer a much-needed solution to support novel gene therapy development.

Dr Arron Tolley, CEO of Aptamer Group said: ‘I am delighted to have established this agreement to develop Optimer binders to enable inducible treatments in this exciting field of gene therapy. We will be working closely with our partner Flip Gene Therapeutics on developing and assessing the Optimer binders to function as part of their gene therapy platform. The interest in pursuing Optimer binders as part of their therapeutic modality offers a strong endorsement of the technology.’

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine